Search alternatives:
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
wt decrease » _ decrease (Expand Search), nn decrease (Expand Search), awd decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
i wt » _ wt (Expand Search), i w (Expand Search), i et (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
wt decrease » _ decrease (Expand Search), nn decrease (Expand Search), awd decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
i wt » _ wt (Expand Search), i w (Expand Search), i et (Expand Search)
-
4861
-
4862
Atrial and ventricular connexins and sodium channel genes expression levels in wt and Ts65Dn mice.
Published 2012“…Ts65Dn show an overall decrease in connexin and sodium channel mRNA expression except for <i>Cx45</i> and <i>Cx30.2</i> in the atria. …”
-
4863
Cytoplasmic deadenylase Ccr4 is required for translational repression of <i>LRG1</i> mRNA in the stationary phase
Published 2017“…In the log-phase <i>ccr4Δ</i> mutant cells, <i>LRG1</i> poly(A) tail was longer and <i>LRG1</i> mRNA level was higher than those in the log-phase wild-type (WT) cells. …”
-
4864
Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease
Published 2022“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”
-
4865
Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease
Published 2022“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”
-
4866
Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease
Published 2022“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”
-
4867
Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease
Published 2022“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”
-
4868
Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease
Published 2022“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”
-
4869
Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease
Published 2022“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”
-
4870
Methodology.
Published 2024“…Upon binding of lactate YFP and CFP move farther apart, the intensity of YFP fluorescence decreases while that of CFP increases. This leads to a decrease in the YFP/CFP FRET ratio. …”
-
4871
-
4872
T Cell Leukemia/Lymphoma 1A is essential for mouse epidermal keratinocytes proliferation promoted by insulin-like growth factor 1
Published 2018“…In particular, the colony-forming efficiency (CFE) and the insulin-like growth factor 1 (IGF1)-induced proliferation are dramatically impaired, while apoptosis is increased, in KCs from <i>Tcl1-/-</i> mice when compared to WT. …”
-
4873
-
4874
-
4875
-
4876
Nur77 expression by thymocytes and peripheral T cells in WT and Nur77Tg mice.
Published 2008“…Thymuses from WT or Nurr77Tg mice were stained with CD4, CD8, CD25 and CD44 Abs; left upper panel showed the proportions of single positive (CD4+ or CD8+), double positive and double negative cells, and left lower panel shows analysis of the double negative (DN) population 1–4 based on CD44 and CD25 expression. …”
-
4877
-
4878
-
4879
-
4880